
    
      PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled study. Patients are
      randomized into one of three treatment groups. The first group receives placebo. The second
      group receives low dose albuterol orally every 12 hours. The third group receives high dose
      albuterol orally every 12 hours. Treatment continues for 52 weeks unless unacceptable side
      effects occur.

      All patients return for follow up assessments at weeks 4, 12, 24, and 52.

      Completion date provided represents the completion date of the grant per OOPD records
    
  